Pembrolizumab for advanced throat cancer to avoid laryngectomy
Treatments studied
Part of Cancer, Ear, nose & throat, Lungs & breathing clinical trials.
This trial tests whether a drug called pembrolizumab (Keytruda) can help people with advanced throat cancer avoid removal of the voice box. You may be eligible if you have a specific type of larynx or hypopharynx cancer that hasn't been treated with radiation or immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of throat cancer called squamous cell carcinoma of the larynx or hypopharynx.
- Your cancer must be at stage III, IVA, or IVB, and your doctors believe surgery to remove the larynx is an option.
- You must have a fresh tumor biopsy that shows a specific protein (PD-L1) at a certain level (CPS ≥ 1).
- You cannot have had prior treatment with immunotherapy drugs like pembrolizumab or radiation therapy.
- You must be in good general health (ECOG score 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
This study tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy before surgery. The goal is to shrink the tumor enough to save the voice box (larynx), instead of removing it. It is for people with advanced throat cancer that can be removed by surgery.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This trial tests whether giving a combination of an immunotherapy drug (PD-1 inhibitor) and chemotherapy before surgery can help treat advanced throat cancer. The goal is to see if this approach shrinks tumors and improves outcomes.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy before surgery improves outcomes for people with advanced laryngeal or hypopharyngeal cancer. The treatment is given before your planned total laryngectomy, and the goal is to shrink the tumor and potentially improve long-term results.
This trial tests whether a combination of immunotherapy and chemotherapy before surgery can help people whose throat cancer has come back after treatment. The goal is to shrink the tumor before surgery, which may improve outcomes.
Hear when a new Hypopharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.